Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs. We are pleased to share that they have dosed the first participant in the ELEVATE-44-201 clinical trial for individuals with Duchenne amenable to skipping Exon 44. They expect to report clinical data from the first cohort during the first half of 2026. This study is currently enrolling ambulatory participants in the UK, Belgium, Italy, and Spain, and expects to begin enrolling in the US in 2026.
In addition, the ELEVATE-25-201 study for ambulatory individuals amenable to skipping Exon 45 is also enrolling in the UK, Belgium, Italy, and Spain, with the first participant expected to be dosed Q3 2025.
Entrada also plans to submit global regulatory filings for an Exon-50 skipping program in the UK and EU in Q4 2025, and for an Exon-51 skipping program in the UK and EU in 2026.
Link to press release: https://www.globenewswire.com/news-release/2025/08/06/3128180/0/en/Entrada-Therapeutics-Reports-Second-Quarter-2025-Financial-Results.html
The post Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs appeared first on CureDuchenne.